Article Figures & Data
Figures
- FIGURE 1.
Longitudinal biodistribution of 177Lu-rhPSMA-10.1 in non–tumor-bearing BALB/c mice (A) and 22Rv1 xenograft–bearing SCID mice (B).
- FIGURE 2.
(A) Kidney uptake of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in BALB/c mice. (B) Blood clearance of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in BALB/c mice. (C) Tumor and kidney uptake of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in 22Rv1 xenograft–bearing SCID mice at single time point. *P ≤ 0.05. **P ≤ 0.01. ***P ≤ 0.001.
- FIGURE 3.
Therapeutic efficacy and tolerability of single administration of 177Lu-rhPSMA-10.1 (15, 30, and 45 MBq) in LNCaP tumor–bearing mice: relative tumor volume (A), survival (B), and relative body weight (C).
- FIGURE 4.
Therapeutic efficacy and tolerability of single administration (30 MBq) of 177Lu-rhPSMA-10.1 in 22Rv1 tumor–bearing mice, compared with 177Lu-PSMA-617 and 177Lu-PSMA-I&T: relative tumor volume (A), survival (B), and relative body weight (C).
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.